Invitae

Invitae R&D / Revenue

Delisted

The R&D to Revenue Ratio of Invitae (NVTAQ) as of Oct 14, 2026 is 52.50 %. In the previous year, R&D to Revenue Ratio was 76.35 % — a change of -31.24% (lower).

R&D / Revenue

52.50 %

YoY

-31.24%

Last updated:

R&D to Revenue Ratio of Invitae is 2023 52.50 % . R&D to Revenue Ratio of Invitae was 2022 76.35 % . It decreases by -31.24% lower compared to the previous year.

The Invitae R&D / Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D / Revenue
Date
R&D / Revenue
Jan 1, 2016
178.18 USD
Jan 1, 2017
68.12 USD
Jan 1, 2018
42.99 USD
Jan 1, 2019
65.27 USD
Jan 1, 2020
85.76 USD
Jan 1, 2021
78.95 USD
Jan 1, 2022
76.35 USD
Jan 1, 2023
52.50 USD
The Invitae R&D / Revenue history
YEARR&D / RevenueYoY
52.50 %-31.24%
76.35 %-3.29%
78.95 %-7.95%
85.76 %+31.39%
65.27 %+51.83%
42.99 %-36.89%
68.12 %-61.77%
178.18 %-65.13%
510.93 %-62.98%
1,380.30 %—
Access this data via the Eulerpool API

Invitae Stock analysis

What does Invitae do? Invitae Corp is a US-based company specialized in providing genetic tests for the diagnosis, treatment, and prevention of diseases. It was founded in 2010 and is headquartered in San Francisco, California. The company's goal is to lower the cost of genetic testing and increase accessibility for patients through automation and sample pooling methods. Invitae has received significant funding and has expanded its capital through multiple rounds of investments from venture capital firms, totaling nearly half a billion dollars. Its business model focuses on offering genetic tests to a wide range of patient groups, streamlining the testing processes through automation and software optimization. Invitae serves consumers directly, as well as medical professionals, hospitals, health centers, laboratories, and health insurance companies. The company aims to improve disease diagnosis and early detection while promoting long-term patient health. Invitae has broadened its capabilities through strategic acquisitions and partnerships, consolidating genetic data on a single platform. It offers a diverse portfolio of genetic tests for the diagnosis, treatment, and prevention of various diseases, including cancer predisposition, cardiovascular diseases, rare inherited diseases, neurological disorders, and medical genomics. The company also provides genetic counseling and family-oriented diagnosis services, along with an online platform facilitating interactive communication between doctors and patients, enabling the sharing and presentation of genetic information and test results. Invitae is an innovative company that has established itself as a market leader in genetic testing, offering a wide range of products and services facilitated by advanced technologies and data storage solutions. The recent acquisitions and partnerships have expanded Invitae's portfolio, improved its technology platform, and strengthened its position as a provider of high-quality healthcare services, enabling well-informed decision-making for patients and medical professionals. Invitae is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Invitae stock

R&D to Revenue Ratio of Invitae is 52.50 % in 2023.

R&D to Revenue Ratio of Invitae changed from 76.35 % to 52.50 %, representing a -31.24% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of R&D to Revenue Ratio Invitae since 2006 – with annual values, charts, and detailed analysis.

The R&D to Revenue ratio shows what percentage of revenue a company invests in research and development. Higher ratios indicate stronger focus on innovation.

A 'good' varies by industry and company stage. On Eulerpool, you can compare R&D to Revenue Ratio's Invitae with sector peers and the industry average to assess whether it is attractive.

To evaluate R&D to Revenue Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for R&D to Revenue Ratio.

Access this data via the Eulerpool API

Margins — Invitae

All Key Metrics — Invitae